



**SASKATCHEWAN FORMULARY BULLETIN  
UPDATE TO THE  
59th EDITION OF THE  
SASKATCHEWAN FORMULARY**

**NEW FULL FORMULARY  
LISTINGS EFFECTIVE  
DECEMBER 1, 2009:**

- Bimatoprost, ophthalmic solution, 0.01% (Lumigan-ALL)

**NEW EXCEPTION DRUG STATUS  
LISTINGS EFFECTIVE  
DECEMBER 1, 2009:**

- Calcium acetate, tablet, 667mg (PhosLo-FMC)

For treatment of:

- a) End-stage renal disease in patients intolerant to aluminum or calcium containing phosphate-binding agents.
- b) End-stage renal disease in patients where aluminum or calcium containing phosphate-binding agents are inappropriate.

- Interferon Beta-1A, pre-filled cartridge, 66mcg/1.5mL, (3 doses of 22 mcg), 132mcg/1.5mL (3 doses of 44mcg) (Rebif-SRO)

For coverage according to the current criteria for interferon Beta-1A.

- Trospium chloride, tablet, 20mg (Trosec-ORX)

For treatment of patients intolerant to oxybutynin chloride.

**REVISED EXCEPTION DRUG  
STATUS CRITERIA EFFECTIVE  
DECEMBER 1, 2009:**

- Tenofovir disoproxil fumarate, tablet, 300mg (Viread-GSK)

For treatment of:

- a) HIV in patients who have failed an alternative nucleoside reverse transcriptase inhibitor.
- b) HIV in patients intolerant to an alternative nucleoside reverse transcriptase inhibitor.

This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

c) Chronic hepatitis B infection in patients with cirrhosis documented on radiologic or histologic grounds and a HBV DNA concentration above 2000 IU/mL.

**NEW INTERCHANGEABLE FULL  
FORMULARY OR EDS LISTINGS  
EFFECTIVE NOVEMBER 1, 2009:**

- Azithromycin, oral suspension, 20mg/mL, 40mg/mL (Sandoz Azithromycin-SDZ)
- Fentanyl, transdermal system, 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr (Ran-Fentanyl Matrix-RAN)
- Nifedipine, extended release tablet, 60mg (Mylan-Nifedipine XL-MYL)
- Olanzapine, orally disintegrating tablet, 5mg, 10mg, 15mg (Novo-Olanzapine OD-NOP) (pms-Olanzapine ODT-PMS)
- Olanzapine, tablet, 2.5mg, 5mg, 7.5mg, 10mg, 15mg (Novo-Olanzapine-NOP) (pms-Olanzapine-PMS)
- Quetiapine, tablet, 25mg, 100mg, 200mg, 300mg (Jamp-Quetiapine-JPC)
- Salbutamol sulfate, metered dose inhaler, 100 mcg/dose (Ventolin HFA-GSK)
- Simvastatin, tablet, 5mg, 10mg, 20mg, 40mg, 80mg (Jamp-Simvastatin-JPC)

**DRUGS REVIEWED AND NOT  
RECOMMENDED**

The Committee supports the CEDAC recommendation that the following products not be listed:

- Teriparatide (rDNA origin), pre-filled pen, 250mcg/mL (Forteo-LIL)
- Levodopa/carbidopa, intestinal gel, 20mg/mL/5mg/mL (Duodopa-SLV)

**RECOMMENDED FOR DELISTING  
EFFECTIVE DECEMBER 1, 2009:**

- Flavoxate HCl, tablet, 200mg (Apo-Flavoxate-APX)

The Saskatchewan Formulary Committee (SFC) have recommended that Apo-Flavoxate 200mg be delisted from the Formulary due to the high cost of this drug relative to other listed alternatives and insufficient evidence to support continued listing of this product. For those patients currently taking the drug, coverage will continue i.e. they will be GRANDFATHERED.

**FROM THE ADVISORY  
COMMITTEE ON INSTITUTIONAL  
PHARMACY PRACTICE (ACIPP):**

- Fondaparinux sodium, injection, 2.5mg/0.5mL, 7.5mg/0.6mL (Arixtra-GSK)

For the treatment of heparin-induced thrombocytopenia (HITT).

**Note:** the brand name will not appear in the HBDL as only generic names are published in this list.